Abstract
After the experimental and phase one studies of our so-called "artificial blood," Fluosol-DA (20%), an emulsified mixture of perfluorodecalin and perfluorotripropylamine, were successfully completed, phase two and three clinical studies were carried out on 186 patients in Japan. The initial dose was 20 ml/Kg body weight (BW), and additional 10 ml/Kg BW doses were applied as needed. Oxygen-supplying and plasma-extending effects were established. No untoward reaction was observed in any of the 186 cases except in a case that involved long-term repeated administration. Initial studies on FLuosol-DA suggest reasonable safety; however, additional clinical trials appear warranted.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Honda K., Hoshino S., Shoji M., Usuba A., Motoki R., Tsuboi M., Inoue H., Iwaya F. Clinical use of a blood substitute. N Engl J Med. 1980 Aug 14;303(7):391–392. doi: 10.1056/NEJM198008143030710. [DOI] [PubMed] [Google Scholar]
- Tremper K. K., Lapin R., Levine E., Friedman A., Shoemaker W. C. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%). Crit Care Med. 1980 Dec;8(12):738–741. doi: 10.1097/00003246-198012000-00009. [DOI] [PubMed] [Google Scholar]